{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:19:21Z","timestamp":1770142761783,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05475-0","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T05:01:26Z","timestamp":1697605286000},"page":"185-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed\/refractory follicular lymphoma"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-3234","authenticated-orcid":false,"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin I.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oreofe O.","family":"Odejide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"5475_CR1","doi-asserted-by":"publisher","unstructured":"Sureda A, Zhang MJ, Dreger P et al (2018) Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer 124. https:\/\/doi.org\/10.1002\/cncr.31264","DOI":"10.1002\/cncr.31264"},{"key":"5475_CR2","doi-asserted-by":"publisher","unstructured":"Evens AM, Vanderplas A, Lacasce AS et al (2013) Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 119. https:\/\/doi.org\/10.1002\/cncr.28243","DOI":"10.1002\/cncr.28243"},{"key":"5475_CR3","doi-asserted-by":"publisher","unstructured":"Jacobson CA, Chavez JC, Sehgal AR et al (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"5475_CR4","doi-asserted-by":"publisher","unstructured":"Fowler NH, Dickinson M, Dreyling M et al (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28. https:\/\/doi.org\/10.1038\/s41591-021-01622-0","DOI":"10.1038\/s41591-021-01622-0"},{"key":"5475_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23:1055\u20131065. https:\/\/doi.org\/10.1016\/S1470-2045(22)00335-7","journal-title":"Lancet Oncol"},{"key":"5475_CR6","doi-asserted-by":"publisher","unstructured":"Pangault C, Am\u00e9-Thomas P, Rossille D et al (2020) Integrative analysis of cell crosstalk within follicular lymphoma cell niche: towards a definition of the FL supportive synapse. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12102865","DOI":"10.3390\/cancers12102865"},{"key":"5475_CR7","doi-asserted-by":"publisher","unstructured":"Am\u00e9-Thomas P, le Priol J, Yssel H et al (2012) Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26. https:\/\/doi.org\/10.1038\/leu.2011.301","DOI":"10.1038\/leu.2011.301"},{"key":"5475_CR8","doi-asserted-by":"publisher","unstructured":"Yang ZZ, Kim HJ, Wu H et al (2020) TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti\u2013PD-1 response in follicular lymphoma. Clin Cancer Res 26. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0558","DOI":"10.1158\/1078-0432.CCR-20-0558"},{"key":"5475_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood.2019004753","volume":"137","author":"P Armand","year":"2021","unstructured":"Armand P, Janssens A, Gritti G et al (2021) Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma. Blood 137:637\u2013645. https:\/\/doi.org\/10.1182\/blood.2019004753","journal-title":"Blood"},{"key":"5475_CR10","doi-asserted-by":"publisher","unstructured":"Kuruvilla J, Armand P, Hamadani M et al (2022) Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leuk Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2022.2136956","DOI":"10.1080\/10428194.2022.2136956"},{"key":"5475_CR11","doi-asserted-by":"publisher","unstructured":"Gopal AK, Levy R, Houot R et al (2020) First-in-human study of utomilumab, a 4-1BB\/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas. Clin Cancer Res 26. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2973","DOI":"10.1158\/1078-0432.CCR-19-2973"},{"key":"5475_CR12","doi-asserted-by":"publisher","unstructured":"Nastoupil LJ, Chin CK, Westin JR et al (2022) Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 6. https:\/\/doi.org\/10.1182\/bloodadvances.2021006240","DOI":"10.1182\/bloodadvances.2021006240"},{"key":"5475_CR13","doi-asserted-by":"publisher","unstructured":"Alfaro C, Echeveste JI, Rodriguez-Ruiz ME et al (2015) Functional expression of CD137 (4-1BB) on T helper follicular cells. Oncoimmunology 4. https:\/\/doi.org\/10.1080\/2162402X.2015.1054597","DOI":"10.1080\/2162402X.2015.1054597"},{"key":"5475_CR14","doi-asserted-by":"publisher","unstructured":"Voo KS, Foglietta M, Percivalle E et al (2014) Selective targeting of toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135. https:\/\/doi.org\/10.1002\/ijc.28937","DOI":"10.1002\/ijc.28937"},{"key":"5475_CR15","doi-asserted-by":"publisher","unstructured":"Hirano F, Kaneko K, Tamura H et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65. https:\/\/doi.org\/10.1158\/0008-5472.1089.65.3","DOI":"10.1158\/0008-5472.1089.65.3"},{"key":"5475_CR16","doi-asserted-by":"publisher","unstructured":"Lee S-J, Myers L, Muralimohan G et al (2004) 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 173. https:\/\/doi.org\/10.4049\/jimmunol.173.5.3002","DOI":"10.4049\/jimmunol.173.5.3002"},{"key":"5475_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"5475_CR18","doi-asserted-by":"publisher","unstructured":"Carey CD, Gusenleitner D, Lipschitz M et al (2017) Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. https:\/\/doi.org\/10.1182\/blood-2017-03-770719","DOI":"10.1182\/blood-2017-03-770719"},{"key":"5475_CR19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/nar\/gks808","volume":"41","author":"A Klindworth","year":"2013","unstructured":"Klindworth A, Pruesse E, Schweer T et al (2013) Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res 41:e1. https:\/\/doi.org\/10.1093\/nar\/gks808","journal-title":"Nucleic Acids Res"},{"key":"5475_CR20","doi-asserted-by":"crossref","unstructured":"Aronesty E (2013) Comparison of sequencing utility programs. Open Bioinform J 7:1\u20138. https:\/\/openbioinformaticsjournal.com\/VOLUME\/7\/PAGE\/1\/","DOI":"10.2174\/1875036201307010001"},{"key":"5475_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J 17:10\u201312","journal-title":"EMBnet J"},{"key":"5475_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ et al (2016) DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods 13:581\u2013583. https:\/\/doi.org\/10.1038\/nmeth.3869","journal-title":"Nat Methods"},{"key":"5475_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/msb.2011.75","volume":"7","author":"F Sievers","year":"2011","unstructured":"Sievers F, Wilm A, Dineen D et al (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539. https:\/\/doi.org\/10.1038\/msb.2011.75","journal-title":"Mol Syst Biol"},{"key":"5475_CR24","doi-asserted-by":"publisher","first-page":"e9490","DOI":"10.1371\/journal.pone.0009490","volume":"5","author":"MN Price","year":"2010","unstructured":"Price MN, Dehal PS, Arkin AP (2010) FastTree 2\u2014approximately maximum-likelihood trees for large alignments. PLoS One 5:e9490. https:\/\/doi.org\/10.1371\/journal.pone.0009490","journal-title":"PLoS One"},{"key":"5475_CR25","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gks1219","volume":"41","author":"C Quast","year":"2013","unstructured":"Quast C, Pruesse E, Yilmaz P et al (2013) The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41:D590\u2013D596. https:\/\/doi.org\/10.1093\/nar\/gks1219","journal-title":"Nucleic Acids Res"},{"key":"5475_CR26","doi-asserted-by":"publisher","unstructured":"Mallick H et al (2021) Multivariable association discovery in population-scale meta-omics studies. PLOS Computational Biology\u00a017(11):e1009442. https:\/\/doi.org\/10.1371\/journal.pcbi.1009442","DOI":"10.1371\/journal.pcbi.1009442"},{"key":"5475_CR27","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","volume":"23","author":"AW Tolcher","year":"2017","unstructured":"Tolcher AW, Sznol M, Hu-Lieskovan S et al (2017) Phase Ib study of utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res 23:5349\u20135357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1243","journal-title":"Clin Cancer Res"},{"key":"5475_CR28","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC et al (2015) Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 33:3467\u20133474. https:\/\/doi.org\/10.1200\/JCO.2014.59.2139","journal-title":"J Clin Oncol"},{"issue":"14","key":"5475_CR29","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K et al (2019) AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 37(14):1188\u20131199. https:\/\/doi.org\/10.1200\/JCO.19.00010","journal-title":"J Clin Oncol"},{"key":"5475_CR30","doi-asserted-by":"publisher","unstructured":"Rummel M, Kaiser U, Balser C et al (2016) Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 17. https:\/\/doi.org\/10.1016\/S1470-2045(15)00447-7","DOI":"10.1016\/S1470-2045(15)00447-7"},{"key":"5475_CR31","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L et al (2017) Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 35:3898\u20133905. https:\/\/doi.org\/10.1200\/JCO.2017.75.4648","journal-title":"J Clin Oncol"},{"key":"5475_CR32","doi-asserted-by":"publisher","unstructured":"Tobinai K, Igarashi T, Itoh K et al (2011) Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci:102. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02001.x","DOI":"10.1111\/j.1349-7006.2011.02001.x"},{"key":"5475_CR33","doi-asserted-by":"publisher","unstructured":"Diefenbach CS, Peters BA, Li H et al (2021) Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma. Blood Adv:5. https:\/\/doi.org\/10.1182\/bloodadvances.2020003129","DOI":"10.1182\/bloodadvances.2020003129"},{"key":"5475_CR34","doi-asserted-by":"publisher","unstructured":"Smith M, Dai A, Ghilardi G et al (2022) Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med 28. https:\/\/doi.org\/10.1038\/s41591-022-01702-9","DOI":"10.1038\/s41591-022-01702-9"},{"key":"5475_CR35","doi-asserted-by":"publisher","unstructured":"Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359. https:\/\/doi.org\/10.1126\/science.aan3706","DOI":"10.1126\/science.aan3706"},{"key":"5475_CR36","doi-asserted-by":"publisher","unstructured":"Matson V, Fessler J, Bao R et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359. https:\/\/doi.org\/10.1126\/science.aao3290","DOI":"10.1126\/science.aao3290"},{"key":"5475_CR37","doi-asserted-by":"publisher","unstructured":"Derosa L, Routy B, Thomas AM et al (2022) Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 28. https:\/\/doi.org\/10.1038\/s41591-021-01655-5","DOI":"10.1038\/s41591-021-01655-5"},{"key":"5475_CR38","doi-asserted-by":"publisher","unstructured":"Jin Y, Dong H, Xia L et al (2019) The diversity of gut microbiome is associated with favorable responses to anti\u2013programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol 14. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.007","DOI":"10.1016\/j.jtho.2019.04.007"},{"key":"5475_CR39","doi-asserted-by":"publisher","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359. https:\/\/doi.org\/10.1126\/science.aan4236","DOI":"10.1126\/science.aan4236"},{"key":"5475_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-022-04985-7","volume":"608","author":"M Bae","year":"2022","unstructured":"Bae M, Cassilly CD, Liu X et al (2022) Akkermansia muciniphila phospholipid induces homeostatic immune responses. Nature 608:168\u2013173. https:\/\/doi.org\/10.1038\/s41586-022-04985-7","journal-title":"Nature"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05475-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05475-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05475-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:03:53Z","timestamp":1704218633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05475-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5475"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05475-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RWM \u2014 Consulting: Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Intellia, Epizyme. Research funding: Bristol Myers Squibb, Merck, Genentech\/Roche, Genmab.RAR \u2014 none.ASF \u2014 none.IEA \u2014 Consulting: BeiGene.JRB \u2014 consultant for Abbvie, Acerta\/Astra-Zeneca, BeiGene, Eli Lilly, Genentech\/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, MEI Pharma, Numab Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo\/Lilly, MEI Pharma, SecuraBio, TG Therapeutics.JLC \u2014 Consultancy: Karyopharm, Kite, Morphosys, Incyte, ADC Therapeutics, Research Funding: Genentech\/Roche, Merck, Abbvie, Bayer.MSD \u2014 consulting fees from AbbVie, Adaptive Biosciences, Aptitude Health, Ascentage Pharma, AstraZeneca, BeiGene, Bio Ascend, BMS, Celgene, Curio Science, Eli Lilly, Genentech, Janssen, Merck, Ono Pharmaceuticals, Research to Practice, Secura Bio, TG Therapeutics, Takeda, and research support from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics.DCF \u2014 none.EDJ \u2014 Consulting: Syros, Takeda. Research funding: Acerta, Janssen, Novartis, Pharmacyclics.AIK \u2014 none.ASL \u2014 Consulting: Research to Practice. Advisory ad boards: Kite and Seagen.SN \u2014 none.OOO \u2014 none.EMP \u2014 none.II \u2014 consultant for Celgene\/Jazz, Kite, Epizyme, Beam Therapeutics, and ADC Therapeutics.JK \u2014 Consulting: Merck, ADC Therapeutics, Gilead, Daiichi Sankyo, BeiGene, SecuraBio. Research support: Merck, SecuraBio. Speakers\u2019 Bureau: Kite\/Gilead.JBC \u2014 Advisory Board: Abbvie, Janssen, Astra Zeneca, BeiGene, Kite, ADCT, Hutchmed, Loxo\/Lilly. Research Funding: Genentech, Takeda, Lilly\/Loxo, Celgene\/BMS, Astra Zeneca, HutchMed.NM-S \u2014 institutional clinical trial funding from AstraZeneca, Bristol Myers-Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech\/Roche, Innate Pharmaceuticals, Secura Bio\/Verastem, Yingli Pharmaceuticals and Dizal Pharmaceuticals. She has received compensation for service as a consultant for AstraZeneca, Secura Bio\/Verastem, Daiichi Sankyo, C4 Therapeutics, Genentech, Karyopharm Therapeutics, Kyowa Hakko Kirin, and Ono pharmaceuticals.NLB \u2014 Consultancy\/Advisory Boards: SeaGen, Roche\/Genentech, Kite\/Gilead, Foresight Diagnostics. Research funding (Institution): ADC Therapeutics, BMS\/Celgene, Kite\/Gilead, Merck, Millennium, Pharmacyclics, Roche\/Genentech, SeaGen.MM \u2014 Advisory board: Novartis, Seattle Genetics, CTI, Janssen, EUSA; Speaker\u2019s bureau: Seattle Genetics, Monjuvi.TMK \u2014 none.JOW \u2014 none.SJR \u2014 Research fundings: Bristol Myers Squibb and KITE\/Gilead. Member of the SAB for Immunitas Therapeutics.PA \u2014 Consultancy: Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, Astra Zeneca, Genentech, Xencor. Research funding: Kite. Research funding (institutional): Merck, BMS, Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech\/Roche, IGM. Honoraria: Merck, BMS.CAJ \u2014 Consulting: Kite\/Gilead, Novartis, BMS\/Celgene, bluebird bio, Epizyme, Ipsen, Instil Bio, ImmPACT Bio, Caribou Bio, Morphosys, Miltenyi, Abintus Bio. Research funding: Kite\/Gilead and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}